We are international
Donate
#askdrdurie
webcasts from patient & family seminars
webcasts from medical meetings
imwg conference series
webcasts from other organizations
nlb webcasts
webcast archive
imf webcasts
imf international webcasts
teleconferences
webinars
imf webcasts
teleconferences
i have myeloma
webcasts about the imf
• webcasts   TEXT SIZE   



XIIth International Myeloma Workshop, Day 2, February 27, 2009

  • 07:00-08:00 Current Approaches to Supportive Care in Myeloma – Breakfast Symposium (Sponsored by Celgene)
  • 08:15-10:15 Multiple Myeloma Microenvironment
  • 10:30-12:30 Phase III Studies
  • 13:30-15:00 Phase I/II Studies
  • 13:30-15:00 Clinical - New Agents
  • 13:30-15:00 Clinical - Basic Biology - Research
  • 15:30-17:30 Complete Response As A Marker Of Patient Outcomes (Sponsored by Millennium/Ortho-Biotech)
Complete Program Listing
2009 IMW Friday Sessions

Current Approaches to Supportive Care in Myeloma
Management of problems with stem cell mobilization
XIIth International Myeloma Workshop in Washington, DC
Suzanne Lentszh, M. D.
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Prevention & Management of Drug-Induced Peripheral Neuropathy in Myeloma
Paul Richardson, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts
Multiple Myeloma - Microenvironment
p62 - a Potential Target for Blocking Microenvironmental Support of Myeloma
XIIth International Myeloma Workshop in Washington, DC
David Roodman, M.D.
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Migration and Homing in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Irene Ghobrial, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts
Genes and Proteins of Myeloma Endothelial Cells to Search Specific Targets of the Tumor Vasculature
XIIth International Myeloma Workshop in Washington, DC
Angelo Vacca, M.D.
University of Bari Medical School
Bari, Italy
The Effect of Novel Antimyeloma Agents on Bone Metabolism
XIIth International Myeloma Workshop in Washington, DC
Evangelos Terpos, M.D.
General Air Force Hospital
Athens, Greece
Phase III Studies IFM, U.S. Europe, Others
(IFM) Phase III Studies that have been Completed by the IFM Group in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Philippe Moreau, M.D.
Hôpital de Nantes
Nantes, France
(IFM) Phase III Studies That are On-going and Future Planned studies by the IFM Group in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Michael Attal,M.D.
Hôpital Purpan
Toulouse, France
(US/Canada) "Phase III Studies That have been Completed, Ongoing and Planned by the US Groups in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Sagar Lonial, M.D.
Emory Clinic
Atlanta, Georgia
(US/Canada) "Phase III Studies That have been Completed, Ongoing and Planned by the Canadian Group in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Donna Reece, M.D.
Princess Margaret Hospital
Toronto, Ontario, Canada
(Europe) "Phase III Studies That have been Completed, Ongoing and Planned by Italian and Spanish Groups in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Mario Boccadoro, M.D.
Ospedale San Giovanni Battista
Torino, Italy
(Europe) "Phase III Studies That have been Completed, Ongoing and Planned by Various Northern European Groups in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Pieter Sonneveld, M.D.
University Hospital
Rotterdam, Netherlands
Oral Presentations – Clinical – Phase II/III Studies - I
Lenalidomide, bortezomib, and dexamethasone has notable activity in high-risk frontline myeloma
XIIth International Myeloma Workshop in Washington, DC
Paul Richardson, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts
Bortezomib, dexamethasone, cyclophosphamide, lenalidomide (VDCR) has high efficacy in frontline myeloma
XIIth International Myeloma Workshop in Washington, DC
Shaji Kumar, M.D.
Mayo Clinic
Rochester, Minnesota
Prolonged therapy improves quality of response, and CR associated with superior outcomes, with VMP
XIIth International Myeloma Workshop in Washington, DC
Jean Luc Harousseau, M.D.
Hôpital Hotel Dieu
Nantes, France
A Phase III Study of VMPT versus VMP in newly diagnosed elderly myeloma patients
XIIth International Myeloma Workshop in Washington, DC
Antonio Palumbo, M.D.
Ospedale Molinette
Torino, Italy
MP versus MPT in elderly myeloma patients: the final outcome of the HOVON 49 study
XIIth International Myeloma Workshop in Washington, DC
Pierre Wijermans, M.D.
University Hospital
Rotterdam, Netherlands
First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycin, Dexamethasone (PAD) vs VAD as induction treatment prior to High Dose Melphalan (HDM) in patients with multiple myeloma (MM)
XIIth International Myeloma Workshop in Washington, DC
Pieter Sonneveld, M.D.
University Hospital
Rotterdam, Netherlands

back to top
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421 | USA
Hotline:800-452-2873 or 818-487-7455
©2012 International Myeloma Foundation. All Rights Reserved. 		•about myeloma    | •treatment options | •health professionals   | • support   | • webcasts   | • meetings   | • advocacy   | • fundraising   | • media   | • blogs   | • about imf   | Privacy Statement | Annual Report | Audit Report | Federal Tax Form 990 | Facebook | Twitter | mission statement |